Publications by authors named "Laura Scaltriti"
Purpose: To evaluate the prognostic value of IGF-1R expression on circulating tumor cells (CTCs) in a prospective randomized clinical trial comparing chemotherapy plus metformin with chemotherapy alone in metastatic breast cancer (MBC) patients.
Methods: CTCs were collected at baseline and at the end of chemotherapy. An automated sample preparation and analysis system (CellSearch) were customized for detecting IGF-1R expression.
Purpose: To determine the effectiveness of acupuncture for the management of hot flashes in women with breast cancer.
Patients And Methods: We conducted a pragmatic, randomized controlled trial comparing acupuncture plus enhanced self-care versus enhanced self-care alone. A total of 190 women with breast cancer were randomly assigned.
Purpose: Capecitabine has demonstrated significant activity in metastatic breast and colorectal cancer. During the course of treatment with capecitabine, we observed that a relevant number of patients developed elevated levels of the mean corpuscular volume (MCV) of red blood cells.
Methods: This retrospective analysis reviewed treatment with capecitabine in 35 patients with histologically proven advanced breast and colon cancer.
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
J Clin Oncol
September 2011
Article Synopsis
- Carboplatin/paclitaxel is the standard first-line chemotherapy for advanced ovarian cancer, but the MITO-2 trial tested if carboplatin combined with pegylated liposomal doxorubicin (PLD) could be more effective.
- In this trial, 820 chemotherapy-naive patients were randomly assigned to receive either carboplatin/paclitaxel or carboplatin/PLD every three weeks, with progression-free survival (PFS) as the primary endpoint.
- The results showed that while carboplatin/PLD had similar PFS and overall survival times compared to carboplatin/paclitaxel, it had a different toxicity profile, leading to the conclusion that carboplatin
Purpose: Capecitabine is an oral chemotherapeutic agent, already used in breast and colon cancer. Previous data showed encouraging results in the treatment of recurrent ovarian cancer. The aim of this study was to describe activity and toxicity of capecitabine in patients with platinum resistant or refractory ovarian cancer.
View Article and Find Full Text PDFPurpose: We aimed at investigating the efficacy, tolerability, and quality of life (QOL) of gemcitabine (GEM) compared with pegylated liposomal doxorubicin (PLD) in the salvage treatment of recurrent ovarian cancer.
Patients And Methods: A phase III randomized multicenter trial was planned to compare GEM (1,000 mg/m(2) on days 1, 8, and 15 every 28 days) with PLD (40 mg/m(2) every 28 days) in ovarian cancer patients who experienced treatment failure with only one platinum/paclitaxel regimen and who experienced recurrence or progression within 12 months after completion of primary treatment.
Results: One hundred fifty-three patients were randomly assigned to PLD (n = 76) or GEM (n = 77).
Objective: The study aimed at evaluating the activity and toxicity of gemcitabine monochemotherapy in a unselected series of elderly patients with advanced bladder cancer. The secondary objectives were to establish whether there is a correlation between treatment and Comprehensive Geriatric Assessment (CGA) and, in addition, to determine overall patient survival.
Methods: Treatment consisted of six courses of chemotherapy with gemcitabine at a dosage of 1,200 mg/m2 on days 1 and 8, every 21 days.